Progressive or refractory paediatric solid tumor research hub

Metro-PD1-1708: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors

This study looks at new ways to treat children and teenagers with solid cancers that have come back or haven't responded to usual treatments. It combines a new immune-boosting drug (Nivolumab) with milder chemotherapy to see if it's safe and effective.